FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2799872613> ?p ?o ?g. }

• W2799872613 endingPage "521" @default.
• W2799872613 startingPage "512" @default.
• W2799872613 abstract "Invariant natural killer T (iNKT) cells recognize glycolipid antigens bound to CD1d molecules on antigen-presenting cells. Therapeutic activation of iNKT cells with the xenogeneic glycolipid α-galactosylceramide (α-GalCer) can prevent and reverse tumor growth in murine models, but clinical trials using α-GalCer-stimulated human iNKT cells have shown limited efficacy. We synthesized a series of thioglycoside analogs of α-GalCer with different substituents to the galactose residue and found that two of these compounds, XZ7 and XZ11, bound to CD1d-transfected HeLa cells and activated lines of expanded human iNKT cells. Both compounds stimulated cytolytic degranulation by iNKT cells and while XZ7 preferentially stimulated the production of the antitumor cytokine interferon-γ (IFN-γ), XZ11 preferentially stimulated interleukin-4 (IL-4) production. This biased T helper type 1 effector profile of XZ7 was also evident when iNKT were stimulated with dendritic cells presenting this glycolipid. Separate analysis of the responses of CD4+, CD8α+ and CD4−CD8− iNKT cells indicated that XZ7 preferentially activated CD8α+ iNKT cells, and to a lesser degree, CD4−CD8− iNKT cells. The partial agonist effect of glycolipid XZ7, inducing cytotoxicity and IFN-γ production but not IL-4 production, indicates that specific protumour activities of iNKT cells can be abolished, while preserving their antitumor activities, by introducing structural modifications to α-GalCer. Since XZ7 was much less potent than α-GalCer as an iNKT cell agonist, it is unlikely to be superior to α-GalCer as a therapeutic agent for cancer, but may serve as a parent compound for developing more potent structural analogs." @default.
• W2799872613 created "2018-05-17" @default.
• W2799872613 creator A5011497420 @default.
• W2799872613 creator A5013951293 @default.
• W2799872613 creator A5016890096 @default.
• W2799872613 creator A5020828102 @default.
• W2799872613 creator A5029292030 @default.
• W2799872613 creator A5032626903 @default.
• W2799872613 creator A5039040624 @default.
• W2799872613 creator A5041678671 @default.
• W2799872613 creator A5046551021 @default.
• W2799872613 creator A5057100738 @default.
• W2799872613 creator A5071798264 @default.
• W2799872613 creator A5077711133 @default.
• W2799872613 creator A5079499350 @default.
• W2799872613 date "2018-05-06" @default.
• W2799872613 modified "2023-10-16" @default.
• W2799872613 title "Novel thioglycoside analogs of α-galactosylceramide stimulate cytotoxicity and preferential Th1 cytokine production by human invariant natural killer T cells" @default.
• W2799872613 cites W1748261727 @default.
• W2799872613 cites W1871903510 @default.
• W2799872613 cites W1954055770 @default.
• W2799872613 cites W1987218136 @default.
• W2799872613 cites W1987950952 @default.
• W2799872613 cites W1991083242 @default.
• W2799872613 cites W1995529916 @default.
• W2799872613 cites W2001075408 @default.
• W2799872613 cites W2004122281 @default.
• W2799872613 cites W2007137754 @default.
• W2799872613 cites W2014540590 @default.
• W2799872613 cites W2015194963 @default.
• W2799872613 cites W2024972563 @default.
• W2799872613 cites W2026555862 @default.
• W2799872613 cites W2033119599 @default.
• W2799872613 cites W2033443495 @default.
• W2799872613 cites W2034857439 @default.
• W2799872613 cites W2052054111 @default.
• W2799872613 cites W2059313909 @default.
• W2799872613 cites W2062403869 @default.
• W2799872613 cites W2065363863 @default.
• W2799872613 cites W2069446125 @default.
• W2799872613 cites W2069556438 @default.
• W2799872613 cites W2090046324 @default.
• W2799872613 cites W2091355888 @default.
• W2799872613 cites W2100495456 @default.
• W2799872613 cites W2102355478 @default.
• W2799872613 cites W2114307517 @default.
• W2799872613 cites W2114565147 @default.
• W2799872613 cites W2119695630 @default.
• W2799872613 cites W2121477549 @default.
• W2799872613 cites W2126161157 @default.
• W2799872613 cites W2137181933 @default.
• W2799872613 cites W2137695731 @default.
• W2799872613 cites W2142656879 @default.
• W2799872613 cites W2143220826 @default.
• W2799872613 cites W2150888484 @default.
• W2799872613 cites W2153073920 @default.
• W2799872613 cites W2161307276 @default.
• W2799872613 cites W2167094013 @default.
• W2799872613 cites W2167269208 @default.
• W2799872613 cites W2170316367 @default.
• W2799872613 cites W2170417753 @default.
• W2799872613 cites W2275249553 @default.
• W2799872613 cites W2486708377 @default.
• W2799872613 cites W2620608957 @default.
• W2799872613 cites W2949664443 @default.
• W2799872613 cites W4230553020 @default.
• W2799872613 cites W4248035038 @default.
• W2799872613 doi "https://doi.org/10.1093/glycob/cwy035" @default.
• W2799872613 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29688330" @default.
• W2799872613 hasPublicationYear "2018" @default.
• W2799872613 type Work @default.
• W2799872613 sameAs 2799872613 @default.
• W2799872613 citedByCount "12" @default.
• W2799872613 countsByYear W27998726132018 @default.
• W2799872613 countsByYear W27998726132019 @default.
• W2799872613 countsByYear W27998726132020 @default.
• W2799872613 countsByYear W27998726132021 @default.
• W2799872613 countsByYear W27998726132022 @default.
• W2799872613 countsByYear W27998726132023 @default.
• W2799872613 crossrefType "journal-article" @default.
• W2799872613 hasAuthorship W2799872613A5011497420 @default.
• W2799872613 hasAuthorship W2799872613A5013951293 @default.
• W2799872613 hasAuthorship W2799872613A5016890096 @default.
• W2799872613 hasAuthorship W2799872613A5020828102 @default.
• W2799872613 hasAuthorship W2799872613A5029292030 @default.
• W2799872613 hasAuthorship W2799872613A5032626903 @default.
• W2799872613 hasAuthorship W2799872613A5039040624 @default.
• W2799872613 hasAuthorship W2799872613A5041678671 @default.
• W2799872613 hasAuthorship W2799872613A5046551021 @default.
• W2799872613 hasAuthorship W2799872613A5057100738 @default.
• W2799872613 hasAuthorship W2799872613A5071798264 @default.
• W2799872613 hasAuthorship W2799872613A5077711133 @default.
• W2799872613 hasAuthorship W2799872613A5079499350 @default.
• W2799872613 hasBestOaLocation W27998726131 @default.
• W2799872613 hasConcept C139563560 @default.
• W2799872613 hasConcept C147483822 @default.
• W2799872613 hasConcept C154317977 @default.
• W2799872613 hasConcept C167672396 @default.

• next